Relative increase in IgG antibodies to Pseudomonas aeruginosa 60-kDa GroEL in prediabetic patients with cystic fibrosis.
In recent years research has focused on a possible connection between bacterial infection and development of diabetes mellitus. In this study, serum antibody responses against bacterial antigens in diabetic and nondiabetic patients with cystic fibrosis (CF) were evaluated. The first part of the study included 252 CF patients of whom 46 (18 %) had diabetes. This study showed that precipitating antibodies (precipitins) against Pseudomonas aeruginosa and other bacteria in crossed immunoelectrophoresis, and IgG antibodies against a 60-kD GroEL of P. aeruginosa, were highly variable and positively correlated with age. Patient material matched for age and sex showed no significant difference between diabetic and nondiabetic CF patients in precipitins or IgG antibodies to P. aeruginosa GroEL. Two longitudinal studies of 9 and 5 y using retrospectively selected sera from 29 prediabetic and 29 cross-matched nondiabetic CF patients were performed. As to precipitins against P. aeruginosa, we found no difference between the prediabetic and the nondiabetic group of patients during the study period. The study revealed, however, a significant increase of 24.6 % (p = 0.008) of IgG antibodies against P. aeruginosa 60-kD GroEL, 3-12 mo before the onset of diabetes in patients with CF, compared with an overall increase of 5 % to 6 % per year in both groups during the observation period. This study shows that diabetes in CF appears after a peak of serum IgG antibodies against GroEL and indicates that development of diabetes in CF patients may not only be caused by a progressive fibrosis of the pancreatic tissue, but may be augmented by a short-term specific immunologic reaction, initially triggered by an ongoing and progressive pulmonary infection.
Jensen
P
P
Department of Clinical Microbiology, The National University Hospital, Copenhagen, Denmark.
Johansen
H K
HK
Lanng
S
S
Høiby
N
N
D000293:Adolescent; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology*; D003550:Cystic Fibrosis / Q000097:blood / Q000150:complications / Q000276:immunology / Q000382:microbiology*; D003920:Diabetes Mellitus / Q000097:blood / Q000209:etiology / Q000276:immunology / Q000382:microbiology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000150:complications / Q000276:immunology; D011550:Pseudomonas aeruginosa / Q000276:immunology* / Q000302:isolation & purification
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G